Fostamatinib is an effective second‐line therapy in patients with immune thrombocytopeniaRalph V. Boccia, James B. Bussel, Quentin A. Hill et al.|British Journal of Haematology|2020Cited by 71
Two-Year Safety and Efficacy Outcomes with Fostamatinib in Adult Patients with Immune Thrombocytopenia (ITP): Open-Label Extension to Phase 3 Trial ProgramAnne‐Marie Duliège, James B. Bussel, Donald M. Arnold et al.|Blood|2018Cited by 12